MedTrace Logo

Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in Korean

NCT04218162 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 294

Last updated 2021-04-01

No results posted yet for this study

Summary

A randomized, double-blind, placebo-controlled parallel group study to evaluate efficacy and safety of lasmiditan tablet compared to Placebo in the acute treatment of Migraine

Conditions

  • Acute Migraine

Interventions

DRUG

Lasmiditan 50mg

Lasmiditan 50mg

DRUG

Lasmiditan 100mg

Lasmiditan 100mg

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • IlDong Pharmaceutical Co Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-24
Primary Completion
2020-10-30
Completion
2020-10-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04218162 on ClinicalTrials.gov